 BUFFALO, N.Y., Oct. 11, 2021 GLOBE NEWSWIRE -- Athenex NASDAQ: ATNX, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a Type A meeting with the U.S. Food and Drug Administration FDA regarding the New Drug Application NDA for oral paclitaxel and encequidar Oral Paclitaxel in metastatic breast cancer mBC. The purpose of the meeting was to review with the FDA a proposed design for a new clinical trial intended to address the deficiencies raised in the Complete Response Letter received in February 2021 and discuss the potential regulatory path forward for Oral Paclitaxel in mBC in the U.S. 